Drugs / Muvalaplin
Muvalaplin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06342596 | Mar → May 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05778864 | Mar 2023 → Sep 2024 | impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05038787 | Nov 2021 → Apr 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04472676 | Aug 2020 → Nov 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05563246 | Nov 2022 → Mar 2024 | — | Eli Lilly and Company | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07157774 | Sep 2025 → Mar 2031 expected | atherosclerotic cardiovascular disease, hyperlipoproteinemia | Eli Lilly and Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-18 | Eli Lilly and Company | Results Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose lilly.com ↗
The study demonstrated that muvalaplin significantly reduced elevated Lp(a) levels in adults, meeting its primary endpoint of percent change in Lp(a) from baseline to week 12. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-18 | Eli Lilly and Company | Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose lilly.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muvalaplin | “Muvalaplin is the first, orally administered, small molecule inhibitor of Lp(a), which acts by disrupting binding of apo(a) and apoB, in clinical development.” PMID 39329200 ↗ Sep 2024 |
| Known as | LY3473329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06342596 ↗ |
| Known as | Muvalaplina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802585 ↗ |
| Known as | Muvalapline | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802585 ↗ |
| Action | Inhibit | “Muvalaplin inhibits lipoprotein(a) formation.” PMID 39556768 ↗ Jan 2025 |
| Modality | Small molecule | “Muvalaplin is the first, orally administered, small molecule inhibitor of Lp(a), which acts by disrupting binding of apo(a) and apoB, in clinical development.” PMID 39329200 ↗ Sep 2024 |
| Route | Oral | “LY3473329 administered orally.” NCT04472676 ↗ |